



Doncaster Place and Bassetlaw Place Medicines Optimisation Bulletin

September 2024



Have you got a spare couple of minutes
?Like what you see? Want to hear more
from Medicines Optimisation? We need
your feedback on the new style bulletin.

Use the QR code opposite or follow the link:
<https://forms.office.com/e/A21uYN9JJb>

Useful hyperlinks for Medicines
Optimisation
To open Press control and click the
link below
[IMOC Webpage](#)
[Doncaster Place Website](#)
[MPD](#)

DIBS Update

You can find latest DIBS information and other useful resources on the DIBS page on the Medicines Management website by clicking this [link](#). If you have any questions around DIBS, please contact the MO team via our email : syicb-doncaster.medicinesmanagementadmin@nhs.net

DIBS related Tips

- To Support the switching of prefilled pens to reusable pens and cartridges there is a power point slide show for prescribers with helpful advice. To watch the presentation [click here](#)
- To help the reduction in salbutamol inhaler prescribing, patients could be moved onto the MART regime to align with the Doncaster Asthma Guidelines for patients over 18 years of age. [Click here](#) for local asthma guidelines
- Different versions of modified-release preparations containing more than 60 mg **diltiazem hydrochloride capsules** may not have the same clinical effect. Prescribers should specify the brand to be dispensed – The brand listed on the Medicines and product directory is **Viazem**.
- There are some useful resources on the medicines management website to support the self-care agenda. To access the self-care web page [click here](#)

Resources to Support Reducing Opioid and Gabapentinoid Prescribing In Non-Cancer Pain (DIBS) – 25 September 24

To access the power point presentation that was presented at this month's Target session [Click Here](#)

Semaglutide (Ozempic) and Tirzepatide(Mounjaro)

Semaglutide (Ozempic) and Tirzepatide(Mounjaro) pens do not come with needles included and so patient will require a prescription for needles, please follow local formulary choices below:-

Pen Needle Formulary Choice (For Insulin Pen Devices)	
1st line Choice – GlucoRx care point insulin needles	2nd Line Choice – BD VIVA
4mm/31 gauge (100) £2.75	4mm/32 gauge (90) £3.59*
5mm/31 gauge (100) £2.75	5mm/31 gauge (90) £3.59
6mm/31 gauge (100) £2.75	6mm/31 gauge (90) £3.59
8mm/31 gauge (100) £2.75	8mm/31 gauge (90) £3.59
*For children and those patients who report discomfort Pen needle 4mm/32 gauge is the preferred option due to shallow and very fine needle.	

There have been some reports of faulty pens and there appears to be a link to the patient not attaching the pen needle correctly or incorrect use of the pen. HCPs or patients can report via the following routes:

- Phone: 01256 315 then press 1 after the automated intro
- Email: to ukmedinfo@lilly.com



Formulary updates September 2024

The following items will be added/amended on the MPD

Formulary Section	Item	Indication	PMOC Formulary Decisions
7.3.2	Drospirenone (Slynd)	Contraception	green 2nd line not for patients with renal impairment
13.7 / 8.2.4	Imiquimod (Aldara)	New Indication added to MPD Small superficial basal cell carcinomas (sBCCs) in adults dermatology specialists	Amber G for the licensed indication of "Small superficial basal cell carcinomas (sBCCs) in adults." The "G" part of Amber G to include that primary care healthcare professionals with a special interest or extra experience in dermatology may initiate, as well as secondary care dermatology specialists
7.3.1	Ethinylestradiol /drospirenone tablets	Contraception	green non-formulary
7.3.1	Gestodene/ethinylestradiol	Contraception	green non-formulary
3.1.3	Aminophylline hydrate	Respiratory indication	Tab Green formulary
2.6.2	Diltiazem - Viazem Brand for capsules	For angina and hypertension	Formulary choice for MR Capsules is Viazem for new patients
6.1.4	Glucogel	Treatment of Hypoglycaemia for people who are drowsy / confused	Green Formulary
2.2.3	Finerenone	Chronic Kidney Disease in Type 2 Diabetes	Amber Shared Care - formulary 3rd line - for CKD management Link to Shared Care Documents Click here
4.8.1	Ethosuximide to Emeside brand	Epilepsy	Add Emeside Brand as 1 st line choice

For the latest Out of Stock information
Refer to your regular emails from medicines management Admin emails.

Donny Dot : Connecting the people of Doncaster to mental health and wellbeing information, advice and support. This bulletin is focusing on the Pain Management Module.
To access this module [click here](#)

Salazopyrin EN® tablets discontinuation
Local position statement
Salazopyrin EN® has recently been re-branded as a generic (Sulfasalazine 500 mg gastro resistant tablets).
There is now limited / no stock available of the Salazopyrin EN® 500mg brand. For full details [click here](#)

Advice to primary care clinicians managing Pancreatic Enzyme Replacement Therapy (PERT)

For the most up-to-date advice for prescribing PERT medication [Click Here](#)

Eclipse Live Update

The data that is captured in Eclipse Live can be used for pathway development and can help to guide future projects. Not only for the Medicines Optimisation team and Practice staff but for commissioning and development of work such as cancer screening and diabetic review.

There are now 30 practices currently signed up and live. If you still have not signed up to Eclipse Live and would like to download a blank contract you can find it by [clicking this link](#)

- If you have asked for access to Eclipse Live, please check your junk mail as the email may go in there. If you have any other issues with log in details please contact support@prescribingservices.org this is maintained by a dedicated support team who will pick up and action your request as soon as possible.
- You can also request support with Eclipse Live by contacting the ICB SY Digital Transformation Product Support Team via this email: syicb-rotherham.dataqualityanddigitaloptimisationteams@nhs.net

Emollient Prescribing Guidance for long term conditions only

This guidance has been recently updated with the 1st line formulary choices of products for long term conditions. It is available to view on the MO website.
To view the full document [Click Here](#)

Contact us : South Yorkshire Integrated Care Board Doncaster Place Medicines Optimisation Team

Phone: 03000 213394

E-mail: syicb-doncaster.medicinesmanagementadmin@nhs.net (general enquiries) or syicb-doncaster.rxline@nhs.net (Clinical Enquiries)